biostudies-literatureUnknown14(11)Manuel Sousa JAbbVie<h4>Aim</h4>We describe the effectiveness and safety of the interferon-free regimen ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin (OBV/PTV/r ± DSV ± RBV) in a nationwide representative sample of the hepatitis C virus (HCV) monoinfected and human immunodeficiency virus-1/hepatitis C virus (HIV/HCV) coinfected population in Spain.<h4>Material and methods</h4>Data were collected from patients infected with HCV genotypes 1 or 4, with or without HIV-1 coinfection, treated with OBV/PTV/r ± DSV ± RBV at 61 Spanish sites within the initial implementation year of the first government-driven "National HCV plan." Effectiveness was assessed by sustained virologic response at post-treatment week 12 (SVR12) and compared between monoinfected and coinfected patients using a noPloS onee0225061https://www.ebi.ac.uk/biostudies/studies/S-EPMC6850697biostudies-literatureReal-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.PMC6850697Rodriguez MEspinosa NMagaz MMateos-Munoz BSanchez Antolin GPulido FGallego AAguilar PCarnicer FMoreno-Planas JMVergara MManzanares ADelgado MRico MMenendez FMoran-Sanchez SHernandez-Guerra MJou ARubin AManuel Sousa JZozaya JMGarcia-Buey LAldamiz-Echevarria TCarrion JARincon DChimeno-Hernandez SPolo-Lorduy BEstebanez ASampedro BLorente SIzquierdo SAndrade RJVon-Wichmann MAHijona LSalmeron JEscarda AMorillas RMMartin-Granizo IMorano LfalseReal-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.<h4>Aim</h4>We describe the effectiveness and safety of the interferon-free regimen ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin (OBV/PTV/r ± DSV ± RBV) in a nationwide representative sample of the hepatitis C virus (HCV) monoinfected and human immunodeficiency virus-1/hepatitis C virus (HIV/HCV) coinfected population in Spain.<h4>Material and methods</h4>Data were collected from patients infected with HCV genotypes 1 or 4, with or without HIV-1 coinfection, treated with OBV/PTV/r ± DSV ± RBV at 61 Spanish sites within the initial implementation year of the first government-driven "National HCV plan." Effectiveness was assessed by sustained virologic response at post-treatment week 12 (SVR12) and compared between monoinfected and coinfected patients using a no2019-01-01T00:00:00Z20192026-04-29T11:32:12.632Z2020-05-21T19:56:48ZS-EPMC68506973171495010.1371/journal.pone.0225061